France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €115.00. The ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

Sanofi is scheduled to report results for the first quarter on Thursday. Here is what you need to know. BUSINESS OPERATING PROFIT FORECAST: The French pharmaceutical company is expected to make 2. ...